LifeTech Scientific (SEHK:1302) - Aandelenkoers, Nieuws & Analyse

1302 Overzicht aandelen

LifeTech Scientific Corporation, een investeringsmaatschappij, ontwikkelt, produceert en handelt in interventionele medische hulpmiddelen voor cardiovasculaire en perifere vaatziekten en -aandoeningen wereldwijd. Meer informatie

1302 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	5/6
Prestaties in het verleden	1/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 29.5% per jaar groeien

Risicoanalyse

Grote eenmalige posten die de financiële resultaten beïnvloeden

Winstmarges (19.4%) zijn lager dan vorig jaar (28%)

LifeTech Scientific Corporation Concurrenten

AK Medical Holdings

SEHK:1789

HK$5.5b

LEPU ScienTech Medical Technology (Shanghai)

SEHK:2291

HK$6.1b

MicroPort NeuroScientific

SEHK:2172

HK$5.6b

Beijing Chunlizhengda Medical Instruments

SEHK:1858

HK$5.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor LifeTech Scientific
Historische aandelenkoersen
Huidige aandelenkoers	HK$1.50
52 Week Hoogtepunt	HK$2.52
52 Week Laag	HK$1.24
Bèta	0.83
11 maand verandering	6.38%
3 maanden verandering	4.17%
1 Jaar Verandering	-38.78%
33 jaar verandering	-59.79%
5 jaar verandering	14.50%
Verandering sinds IPO	500.00%

Recent nieuws en updates

LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump

Oct 02

Recent updates

LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump

Oct 02

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

Jul 05

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

Apr 25

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Dec 25

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

Nov 28

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

Nov 03

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

Oct 14

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Jul 15

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

Jun 30

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Jun 15

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Apr 03

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Mar 15

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Jan 22

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Dec 19

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Dec 06

Is LifeTech Scientific (HKG:1302) A Risky Investment?

Nov 20

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

Oct 12

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

Sep 13

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

Aug 28

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Aug 13

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Jun 08

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

May 26

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

May 11

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Mar 31

Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%

Feb 21

Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?

Jan 26

Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 13

Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?

Nov 25

Rendement voor aandeelhouders

	1302	HK Medical Equipment	HK Markt
7D	-7.4%	-4.6%	-2.7%
1Y	-38.8%	-37.3%	10.9%

Rendement versus industrie: 1302 presteerde slechter dan de Hong Kong Medical Equipment -sector, die het afgelopen jaar een rendement van -37.3 % opleverde.

Rendement versus markt: 1302 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 10.9 % opleverde.

Prijsvolatiliteit

Is 1302's price volatile compared to industry and market?
1302 volatility
1302 Average Weekly Movement	9.9%
Medical Equipment Industry Average Movement	9.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.2%

Stabiele aandelenkoers: 1302 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van 1302 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	1,414	Yuehui Xie	www.lifetechmed.com

LifeTech Scientific Corporation, een investeringsmaatschappij, ontwikkelt, produceert en verhandelt interventionele medische hulpmiddelen voor cardiovasculaire en perifere vaatziekten en -aandoeningen wereldwijd. Het bedrijf is actief in de segmenten Structurele Hartziekten, Perifere Vasculaire Ziekten en Cardiale Pacing en Elektrofysiologie. Tot de producten behoren LAmbre-sluitsystemen voor de linkerhartboezem, evenals CeraFlex, Cera, HeartR en Konar-MF VSD-afsluiters; Ankura thoracale aneurysma- en abdominale aorta aneurysma stenttransplantaatsystemen; Futhrough endovasculaire naaldsystemen; toedieningssystemen, zoals Fustar stuurbare en SteerEase introducers; Zoetrack voerdraad; Aegisy vena cava filters; Cera vasculaire plugsystemen; AcuMark maatballonnen; HearTone implanteerbaar hartstimulatiesysteem; en SeQure snare systemen, evenals pacemakers.

LifeTech Scientific Corporation Samenvatting

Hoe verhouden de winst en inkomsten van LifeTech Scientific zich tot de beurswaarde?
1302 fundamentele statistieken
Marktkapitalisatie	HK$6.95b
Inkomsten(TTM)	HK$267.76m
Inkomsten(TTM)	HK$1.38b

25.9x

Koers/Winstverhouding

5.0x

P/S-verhouding

Is 1302 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
1302 resultatenrekening (TTM)
Inkomsten	CN¥1.28b
Kosten van inkomsten	CN¥274.29m
Brutowinst	CN¥1.01b
Overige uitgaven	CN¥757.58m
Inkomsten	CN¥248.64m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.054
Brutomarge	78.58%
Nettowinstmarge	19.42%
Schuld/Eigen Vermogen Verhouding	2.9%

Hoe presteerde 1302 op de lange termijn?

Bekijk historische prestaties en vergelijking

1302 Overzicht aandelen

Beloningen

Risicoanalyse

LifeTech Scientific Corporation Concurrenten

SEHK:1789

HK$5.5b

SEHK:2291

HK$6.1b

SEHK:2172

HK$5.6b

SEHK:1858

HK$5.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Investor sentiment improves as stock rises 32%

Investor sentiment deteriorates as stock falls 20%

LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: CN¥0.046 (vs CN¥0.049 in 1H 2023)

New minor risk - Profit margin trend

Recent updates

Investor sentiment improves as stock rises 32%

Investor sentiment deteriorates as stock falls 20%

LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: CN¥0.046 (vs CN¥0.049 in 1H 2023)

New minor risk - Profit margin trend

LifeTech Scientific Corporation to Report First Half, 2024 Results on Aug 30, 2024

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

LifeTech Scientific Corporation Announces One-Year Follow-Up Results of Phase II Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2024

Full year 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.077 in FY 2022)

LifeTech Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

First half 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 in 1H 2022)

Epione Surgical Navigation System Obtained Official Registration Approval by the China NMPA

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

LifeTech Scientific Corporation to Report First Half, 2023 Results on Aug 30, 2023

Is There Now An Opportunity In LifeTech Scientific Corporation (HKG:1302)?

Lifetech Scientific Corporation Announces Enrollment in the Phase Iii Clinical Study of Ibs®? Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

Full year 2022 earnings released: EPS: CN¥0.077 (vs CN¥0.068 in FY 2021)

Investor sentiment improved over the past week

LifeTech Scientific Corporation Announces Enrollment in the China Randomized Controlled Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Insufficient new directors

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

LifeTech Scientific Corporation Announces FDA Approval Investigator-Initiated Pre-Market Clinical Trial of Lambre Plus Laa Closure System Obtained Medical Insurance Coverage in the US

First half 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.047 in 1H 2021)

LifeTech Scientific Corporation to Report Q2, 2022 Results on Aug 30, 2022

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Insufficient new directors

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Full year 2021 earnings: EPS and revenues miss analyst expectations

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2022

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Lifetech Scientific Corporation Announces YuranosTM Abdominal Aortic Stent Graft System Obtained Registration Approval from the China NMPA

Is LifeTech Scientific (HKG:1302) A Risky Investment?

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

First half 2021 earnings released: EPS CN¥0.047 (vs CN¥0.023 in 1H 2020)

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Investor sentiment deteriorated over the past week

LifeTech Scientific Corporation Announces Grant of Medical Device Registration Certificate in Malaysia for Its Self-Developed Ibs Angeltm Iron Bioresorbable Scaffold System

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

Investor sentiment improved over the past week

Non-Executive Director has left the company

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)